To characterize somatic alterations in colorectal carcinoma, we conducted a genome-scale analysis of 276 samples, analysing exome sequence, DNA copy number, promoter methylation and messenger RNA and microRNA expression. A subset of these samples (97) underwent low-depth-of-coverage whole-genome sequencing. In total, 16% of colorectal carcinomas were found to be hypermutated: three-quarters of these had the expected high microsatellite instability, usually with hypermethylation and MLH1 silencing, and one-quarter had somatic mismatch-repair gene and polymerase e (POLE) mutations. Excluding the hypermutated cancers, colon and rectum cancers were found to have considerably similar patterns of genomic alteration. Twenty-four genes were significantly mutated, and in addition to the expected APC, TP53, SMAD4, PIK3CA and KRAS mutations, we found frequent mutations in ARID1A, SOX9 and FAM123B. Recurrent copy-number alterations include potentially drug-targetable amplifications of ERBB2 and newly discovered amplification of IGF2. Recurrent chromosomal translocations include the fusion of NAV2 and WNT pathway member TCF7L1. Integrative analyses suggest new markers for aggressive colorectal carcinoma and an important role for MYC-directed transcriptional activation and repression.
The Cancer Genome Atlas project plans to profile genomic changes in 20 different cancer types and has so far published results on two cancer types 1, 2 . We now present results from multidimensional analyses of human colorectal carcinoma (CRC).
CRC is an important contributor to cancer mortality and morbidity. The distinction between the colon and the rectum is largely anatomical, but it has both surgical and radiotherapeutic management implications and it may have an impact on prognosis. Most investigators divide CRC biologically into those with microsatellite instability (MSI; located primarily in the right colon and frequently associated with the CpG island methylator phenotype (CIMP) and hyper-mutation) and those that are microsatellite stable but chromosomally unstable.
A rich history of investigations (for a review see ref.
3) has uncovered several critical genes and pathways important in the initiation and progression of CRC (ref. 3 ). These include the WNT, RAS2MAPK, PI3K, TGF-b, P53 and DNA mismatch-repair pathways. Large-scale sequencing analyses 4-6 have identified numerous recurrently mutated genes and a recurrent chromosomal translocation. Despite this background, we have not had a fully integrated view of the genetic and genomic changes and their significance for colorectal tumorigenesis. Further insight into these changes may enable deeper understanding of the pathophysiology of CRC and may identify potential therapeutic targets.
Results
Tumour and normal pairs were analysed by different platforms. The specific numbers of samples analysed by each platform are shown in Supplementary Table 1 .
Exome-sequence analysis
To define the mutational spectrum, we performed exome capture DNA sequencing on 224 tumour and normal pairs (all mutations are listed in Supplementary Table 2 ). Sequencing achieved .20-fold coverage of at least 80% of targeted exons. The somatic mutation rates varied considerably among the samples. Some had mutation rates of ,1 per 10 6 bases, whereas a few had mutations rates of .100 per 10 6 . We separated cases (84%) with a mutation rate of ,8.24 per 10 6 (median number of non-silent mutations, 58) and those with mutation rates of .12 per 10 6 (median number of total mutations, 728), which we designated as hypermutated ( Fig. 1) .
To assess the basis for the considerably different mutation rates, we evaluated MSI 7 and mutations in the DNA mismatch-repair pathway [8] [9] [10] genes MLH1, MLH3, MSH2, MSH3, MSH6 and PMS2. Among the 30 hypermutated tumours with a complete data set, 23 (77%) had high levels of MSI (MSI-H). Included in this group were 19 tumours with MLH1 methylation, 17 of which had CIMP. By comparison, the remaining seven hypermutated tumours, including the six with the highest mutation rates, lacked MSI-H, CIMP or MLH1 methylation but usually had somatic mutations in one or more mismatch-repair genes or POLE aberrations seen rarely in the non-hypermutated tumours ( Fig. 1 ).
Gene mutations
Overall, we identified 32 somatic recurrently mutated genes (defined by MutSig 11 and manual curation) in the hypermutated and nonhypermutated cancers (Fig. 1b ). After removal of non-expressed genes, there were 15 and 17 in the hypermutated and non-hypermutated cancers, respectively ( Fig. 1b ; for a complete list see Supplementary  Table 3 ). Among the non-hypermutated tumours, the eight most frequently mutated genes were APC, TP53, KRAS, PIK3CA, FBXW7, SMAD4, TCF7L2 and NRAS. As expected, the mutated KRAS and NRAS genes usually had oncogenic codon 12 and 13 or codon 61 mutations, whereas the remaining genes had inactivating mutations. CTNNB1, SMAD2, FAM123B (also known as WTX) and SOX9 were also mutated frequently. FAM123B is an X-linked negative regulator of WNT signalling 12 , and virtually all of its mutations were loss of function. Mutations in SOX9, a gene important for cell differentiation in the intestinal stem cell niche 13, 14 , have not been associated previously with human cancer, but all nine mutated alleles in the non-hypermutated CRCs were frameshift or nonsense mutations. Tumour-suppressor genes ATM and ARID1A also had a disproportionately high number of frameshift or nonsense mutations. ARID1A mutations have recently been reported in CRC and many other cancers 15, 16 .
In the hypermutated tumours, ACVR2A, APC, TGFBR2, MSH3, MSH6, SLC9A9 and TCF7L2 were frequent targets of mutation ( Fig. 1b ), along with mostly BRAF(V600E) mutations. However, two genes that were frequently mutated in the non-hypermutated cancers were significantly less frequently mutated in hypermutated tumours: TP53 (60 versus 20%, P , 0.0001) and APC (81% versus 51%, P 5 0.0023; both Fisher's exact test). Other genes, including TGFBR2, were mutated recurrently in the hypermutated cancers, but not in the non-hypermutated samples. These findings indicate that hypermutated and non-hypermutated tumours progress through different sequences of genetic events.
As expected, hypermutated tumours with MLH1 silencing and MSI-H showed additional differences in the mutational profile. When we specifically examined 28 genes with long mononucleotide repeats in their coding sequences, we found that the rate of frameshift mutation was 3.6-fold higher than the rate of such mutations in hypermutated tumours without MLH1 silencing and 50-fold higher than that in non-hypermethylated tumours (Supplementary Table 2 ).
Mutation rate and methylation patterns As mentioned above, patients with colon and rectal tumours are managed differently 17 , and epidemiology also highlights differences between the two 17 . An initial integrative analysis of MSI status, somatic copy-number alterations (SCNAs), CIMP status and geneexpression profiles of 132 colonic and 62 rectal tumours enabled us to examine possible biological differences between tumours in the two locations. Among the non-hypermutated tumours, however, the overall patterns of changes in copy number, CIMP, mRNA and miRNA were indistinguishable between colon and rectal carcinomas ( Fig. 2 ). On the basis of this result, we merged the two for all subsequent analyses.
Unsupervised clustering of the promoter DNA methylation profiles of 236 colorectal tumours identified four subgroups (Supplementary Fig. 1 and Supplementary Methods). Two of the clusters contained tumours with elevated rates of methylation and were classified as CIMP high and CIMP low, as previously described 18 . The two non-CIMP clusters were predominantly from tumours that were non-hypermutated and derived from different anatomic locations. mRNA expression profiles separated the colorectal tumours into three distinct clusters ( Supplementary Fig. 2 ). One significantly overlapped with CIMP-high tumours (P 5 3 3 10 212 ) and was enriched with hypermutated tumours, and the other two clusters did not correspond with any group in the methylation data. 
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Chromosomal and sub-chromosomal changes In total, 257 tumours were profiled for SCNAs with Affymetrix SNP 6.0 arrays. Of these tumours, 97 were also analysed by low-depth-ofcoverage (low-pass) whole-genome sequencing. As expected, the hypermutated tumours had far fewer SCNAs (Fig. 2) . No difference was found between microsatellite-stable and -unstable hypermutated tumours ( Supplementary Fig. 4 ). We used the GISTIC algorithm 19 to identify probable gene targets of focal alterations. There were several previously well-defined arm-level changes, including gains of 1q, 7p and q, 8p and q, 12q, 13q, 19q, and 20p and q (ref. 6 ). (Supplementary Fig. 4 and Supplementary Table 4 ). Significantly deleted chromosome arms were 18p and q (including SMAD4) in 66% of the tumours and 17p and q (including TP53) in 56%. Other significantly deleted chromosome arms were 1p, 4q, 5q, 8p, 14q, 15q, 20p and 22q.
We identified 28 recurrent deletion peaks ( Supplementary Fig. 4 and Supplementary Table 4 ), including the genes FHIT, RBFOX1 and WWOX with large genomic footprints located in potentially fragile sites of the genome, in near-diploid hypermutated tumours. Other focal deletions involved tumour-suppressor genes such as SMAD4, APC, PTEN and SMAD3. A significant focal deletion of 10p25.2 spanned four genes, including TCF7L2, which was also frequently mutated in our data set. A gene fusion between adjacent genes VTI1A and TCF7L2 through an interstitial deletion was found in 3% of CRCs and is required for survival of CRC cells bearing the translocation 4 .
There were 17 regions of significant focal amplification (Supplementary Table 4 ). Some of these were superimposed on broad gains of chromosome arms, and included a peak at 13q12.13 near the peptidase-coding gene USP12 and at ,500 kb distal to the CRC candidate oncogene CDK8; an adjacent peak at 13q12; a peak containing KLF5 at 13q22.1; and a peak at 20q13.12 adjacent to HNF4A. Peaks on chromosome 8 included 8p12 (which contains the histone methyl-transferase-coding gene WHSC1L1, adjacent to FGFR1) and 8q24 (which contains MYC). An amplicon at 17q21.1, found in 4% of the tumours, contains seven genes, including the tyrosine kinase ERBB2. ERBB2 amplifications have been described in colon, breast and gastro-oesophageal tumours, and breast and gastric cancers bearing these amplifications have been treated effectively with the anti-ERBB2 antibody trastuzumab [20] [21] [22] .
One of the most common focal amplifications, found in 7% of the tumours, is the gain of a 100-150-kb region of the chromosome arm 11p15.5. It contains genes encoding insulin (INS), insulin-like growth factor 2 (IGF2) and tyrosine hydroxylase (TH), as well as miR-483, which is embedded within IGF2 (Fig. 3a) . We found elevated expression of IGF2 and miR-483 but not of INS and TH (Fig. 3b, c) . Immediately adjacent to the amplified region is ASCL2, a transcription factor active in specifying intestinal stem-cell fate 23 . Although ASCL2 has been implicated as a target of amplification in CRC [23] [24] [25] , it was consistently outside the region of amplification and its expression was not correlated with copy-number changes. These observations suggest that IGF2 and miR-483 are candidate functional targets of 11p15.5 amplification. IGF2 overexpression through loss of imprinting has been implicated in the promotion of CRC 26, 27 . MiR-483 may also have a role in CRC pathogenesis 28 .
A subset of tumours without IGF2 amplification (15%) also had considerably higher levels of IGF2 gene expression (as much as a 100-fold increase), an effect not attributable to methylation changes at the IGF2 promoter. To assess the context of IGF2 amplification/ overexpression, we systematically searched for mutually exclusive genomic events using the MEMo method 29 . We found a pattern of near exclusivity (corrected P , 0.01) of IGF2 overexpression with genomic events known to activate the PI3K pathway (mutations of PIK3CA and PIK3R1 or deletion/mutation of PTEN; Fig. 3c and Supplementary Table 5 ). The IRS2 gene, encoding a protein linking IGF1R (the receptor for IGF2) with PI3K, is on chromosome 13, which is frequently gained in CRC. The cases with the highest IRS2 expression were mutually exclusive of the cases with IGF2 overexpression (P 5 0.04) and also lacked mutations in the PI3K pathway (P 5 0.0001; Fig. 3c ). These results strongly suggest that the IGF2-IGF1R-IRS2 axis signals to PI3K in CRC and imply that therapeutic targeting of the pathway could act to block PI3K activity in this subset of patients.
Translocations
To identify new chromosomal translocations, we performed low-pass, paired-end, whole-genome sequencing on 97 tumours with matched normal samples. In each case we achieved sequence coverage of ,3-4-fold and a corresponding physical coverage of 7.5-10-fold. Despite the low genome coverage, we detected 250 candidate interchromosomal translocation events (range, 0-10 per tumour). Among these events, 212 had one or both breakpoints in an intergenic region, whereas the remaining 38 juxtaposed coding regions of two genes in putative fusion events, of which 18 were predicted to code for in-frame events (Supplementary Table 6 ). We found three separate cases in which the first two exons of the NAV2 gene on chromosome 11 are joined with the 39 coding portion of TCF7L1 on chromosome 2 ( Supplementary Fig. 5 ). TCF7L1 encodes TCF3, a member of the TCF/LEF class of transcription factors that heterodimerize with nuclear b-catenin to enable b-catenin-mediated transcriptional regulation. Intriguingly, in all three cases, the predicted structure of the NAV2-TCF7L1 fusion protein lacks the TCF3 b-catenin-binding domain. This translocation is similar to another recurrent translocation identified in CRC, a fusion in which the amino terminus of VTI1A is joined to TCF4, which is encoded by TCF7L2, a homologue of TCF7L1 that is deleted or mutated in 12% of non-hypermutated tumours 4 . We also observed 21 cases of translocation involving TTC28 located on chromosome 22 ( Supplementary Table 6 ). In all cases the fusions predict inactivation of TTC28, which has been identified as a target of P53 and an inhibitor of tumour cell growth 30 . Eleven of the 19 (58%) gene-gene translocations were validated by obtaining PCR products or, in some cases, sequencing the junction fragments ( Supplementary Fig. 5 ).
Altered pathways in CRC Integrated analysis of mutations, copy number and mRNA expression changes in 195 tumours with complete data enriched our understanding of how some well-defined pathways are deregulated. We grouped samples by hypermutation status and identified recurrent alterations in the WNT, MAPK, PI3K, TGF-b and p53 pathways ( Fig. 4 , Supplementary Fig. 6 and Supplementary Table 1 ). We found that the WNT signalling pathway was altered in 93% of all tumours, including biallelic inactivation of APC (Supplementary Table 7 ) or activating mutations of CTNNB1 in ,80% of cases. There were also mutations in SOX9 and mutations and deletions in TCF7L2, as well as the DKK family members and AXIN2, FBXW7 (Supplementary Fig. 7 ), ARID1A and FAM123B (the latter is a negative regulator of WNT-b-catenin signalling 12 found mutated in Wilms' tumour 31 ). A few mutations in FAM123B have previously been described in CRC 32 . SOX9 has been suggested to have a role in cancer, but no mutations have previously been described. The WNT receptor frizzled (FZD10) was overexpressed in ,17% of samples, in some instances at levels of 1003 normal. Altogether, we found 16 different altered WNT pathway genes, confirming the importance of this pathway in CRC. Interestingly, many of these alterations were found in tumours that harbour APC mutations, suggesting that multiple lesions affecting the WNT signalling pathway confer selective advantage.
Genetic alterations in the PI3K and RAS-MAPK pathways are common in CRC. In addition to IGF2 and IRS2 overexpression, we found mutually exclusive mutations in PIK3R1 and PIK3CA as well as deletions in PTEN in 2%, 15% and 4% of non-hypermutated tumours, respectively. We found that 55% of non-hypermutated tumours have alterations in KRAS, NRAS or BRAF, with a significant pattern of mutual exclusivity ( Supplementary Fig. 6 and Supplementary Table 1 ). We also evaluated mutations in the erythroblastic leukemia viral oncogene homolog (ERBB) family of receptors because of the translational relevance of such mutations. Mutations or amplifications in 
ARTICLE RESEARCH
one of the four ERBB family genes are present in 22 out of 165 (13%) non-hypermutated and 16 out of 30 (53%) hypermutated cases. Some of the mutations are listed in the COSMIC database 33 , suggesting a functional role. Intriguingly, recurrent ERBB2(V842I) and ERBB3(V104M) mutations were found in four and two nonhypermutated cases, respectively. Mutations and focal amplifications of ERBB2 ( Supplementary Fig. 6 ) should be evaluated as predictors of response to agents that target those receptors. We observed co-occurrence of alterations involving the RAS and PI3K pathways in one-third of tumours ( Fig. 4 ; P 5 0.039, Fisher's exact test). These results indicate that simultaneous inhibition of the RAS and PI3K pathways may be required to achieve therapeutic benefit. The TGF-b signalling pathway is known to be deregulated in CRC and other cancers 34 . We found genomic alterations in TGFBR1, TGFBR2, ACVR2A, ACVR1B, SMAD2, SMAD3 and SMAD4 in 27% of the non-hypermutated and 87% of the hypermutated tumours. We also evaluated the p53 pathway, finding alterations in TP53 in 59% of non-hypermutated cases (mostly biallelic; Supplementary Table 8 ) and alterations in ATM, a kinase that phosphorylates and activates P53 after DNA damage, in 7%. Alterations in these two genes showed a trend towards mutual exclusivity (P 5 0.016) ( Fig. 4 , Supplementary  Fig. 6 and Supplementary Table 1 ).
We integrated copy number, gene expression, methylation and pathway data using the PARADIGM software platform 35 . The analysis showed a number of new characteristics of CRC (Fig. 5a ). For example, despite the diversity in anatomical origin or mutation levels, nearly 100% of these tumours have changes in MYC transcriptional targets, both those promoted by and those inhibited by MYC. These findings are consistent with patterns deduced from genetic alterations ( Fig. 4) and suggest an important role for MYC in CRC. The analysis also identified several gene networks altered across all tumour samples and those with differential alterations in hypermutated versus non-hypermutated samples (Supplementary Table 7 , Supplementary Data on the Cancer Genome Atlas publication webpage).
Because most of the tumours used in this study were derived from a prospective collection, survival data are not available. However, the tumours can be classified as aggressive or non-aggressive on the basis of tumour stage, lymph node status, distant metastasis and vascular invasion at the time of surgery. We found numerous molecular signatures associated with tumour aggressiveness, a subset of which is shown in Fig. 5b . They include specific focal amplifications and deletions, and altered gene-expression levels, including those of SCN5A (ref. 36 ), a reported regulator of colon cancer invasion (see Supplementary Tables 10 and 11 for a full list). Association with tumour aggressiveness is also observed in altered expression of miRNAs and specific somatic mutations (APC, TP53, PIK3CA, BRAF and FBXW7; Supplementary Fig. 8b ). Mutations in FBXW7 (38 cases) and distant metastasis (32 cases) never co-occurred (P 5 0.0019). Interestingly, a number of genomic regions have multiple molecular associations with tumour aggressiveness that manifest as clinically related genomic hotspots. Examples of this are the region 20q13.12, which includes a focal amplification and multiple genes correlating with tumour aggression, and the region 22q12.3, containing APOL6 (ref. 37) ( Supplementary Figures 8 and 9 ).
Discussion
This comprehensive integrative analysis of 224 colorectal tumour and normal pairs provides a number of insights into the biology of CRC and identifies potential therapeutic targets. To identify possible biological differences in colon and rectum tumours, we found, in the non-hypermutated tumours irrespective of their anatomical origin, the same type of copy number, expression profile, DNA methylation and miRNA changes. Over 94% had a mutation in one or more members of the WNT signalling pathway, predominantly in APC. However, there were some differences between tumours from the right colon and all other sites. Hypermethylation was more common in the right colon, and three-quarters of hypermutated samples came from the same site, although not all of them had MSI (Fig. 2) . Why most of the hypermutated samples came from the right colon and why there are two classes of tumours at this site is not known. The origins of the colon from embryonic midgut and hindgut may provide an explanation. As the survival rate of patients with high MSI-related cancers is better and these cancers are hypermutated, mutation rate may be a better prognostic indicator. 
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Whole-exome sequencing and integrative analysis of genomic data provided further insights into the pathways that are dysregulated in CRC. We found that 93% of non-hypermutated and 97% of hypermutated cases had a deregulated WNT signalling pathway. New findings included recurrent mutations in FAM123B, ARID1A and SOX9 and very high levels of overexpression of the WNT ligand receptor gene FZD10. To our knowledge, SOX9 has not previously been described as frequently mutated in any human cancer. SOX9 is transcriptionally repressed by WNT signalling, and the SOX9 protein has been shown to facilitate b-catenin degradation 38 . ARID1A is frequently mutated in gynaecological cancers and has been shown to suppress MYC transcription 39 . Activation of WNT signalling and inactivation of the TGF-b signalling pathway are known to result in activation of MYC. Our mutational and integrative analyses emphasize the critical role of MYC in CRC. We also compared our results with other large-scale analyses 6 and found many similarities and few differences in mutated genes (Supplementary Table 3 ).
Our integrated analysis revealed a diverse set of changes in TCF/ LEF-encoding genes, suggesting additional roles for TCF/LEF factors in CRC beyond being passive partners for b-catenin.
Our data suggest a number of therapeutic approaches to CRC. Included are WNT-signalling inhibitors and small-molecule b-catenin inhibitors, which are showing initial promise [40] [41] [42] . We find that several proteins in the RTK-RAS and PI3K pathways, including IGF2, IGFR, ERBB2, ERBB3, MEK, AKT and MTOR could be targets for inhibition.
Our analyses show that non-hypermutated adenocarcinomas of the colon and rectum are not distinguishable at the genomic level. However, tumours from the right/ascending colon were more likely to be hypermethylated and to have elevated mutation rates than were other CRCs. As has been recognized previously, activation of the WNT signalling pathway and inactivation of the TGF-b signalling pathway, resulting in increased activity of MYC, are nearly ubiquitous events in CRC. Genomic aberrations frequently target the MAPK and PI3K pathways but less frequently target receptor tyrosine kinases. In conclusion, the data presented here provide a useful resource for understanding this deadly disease and identifying possibilities for treating it in a targeted way.
METHODS SUMMARY
Tumour and normal samples were processed by either of two biospecimen core resources, and aliquots of purified nucleic acids were shipped to the genome characterization and sequencing centres (Supplementary Methods). The biospecimen core resources provided sample sets in several different batches. To assess any batch effects we examined the mRNA expression, miRNA expression and DNA methylation data sets using a combination of cluster analysis, enhanced principal component analysis and analysis of variance (Supplementary Methods). Although some differences among batches were detected, we did not correct them computationally because the differences were generally modest and because some of them may reflect biological phenomena (Supplementary Methods).
We used Affymetrix SNP 6.0 microarrays to detect copy-number alterations. A subset of samples was subjected to low-pass (2-53) whole-genome sequencing (Illumina HiSeq), in part for detection of SCNA and chromosomal translocations 43, 44 . Gene-expression profiles were generated using Agilent microarrays and RNA-Seq. DNA methylation data were obtained using Illumina Infinium (HumanMethylation27) arrays. DNA sequencing of coding regions was performed by exome capture followed by sequencing on the SOLiD or Illumina HiSeq platforms. Details of the analytical methods used are described in Supplementary Methods.
All of the primary sequence files are deposited in dbGap and all other data are deposited at the Data Coordinating Center (DCC) for public access (http:// cancergenome.nih.gov/). Data matrices and supporting data can be found at http://tcga-data.nci.nih.gov/docs/publications/coadread_2012/. The data can also be explored through the ISB Regulome Explorer (http://explorer.cancerregulome. org/), Next Generation Clustered Heat Maps (http://bioinformatics.mdanderson. org/main/TCGA/Supplements/NGCHM-CRC) and the cBio Cancer Genomics Portal (http://cbioportal.org). Descriptions of the data can be found at https:// wiki.nci.nih.gov/x/j5dXAg and in Supplementary Methods.
